Balance Sheet Components (Tables)

6 Months Ended

Jun. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of reconciliation of total cash, cash equivalents and restricted cash

The following represents a reconciliation of cash and cash equivalents in the condensed consolidated balance sheets to total cash, cash equivalents and restricted cash as of June 30, 2022

and December 31, 2021, respectively, in the condensed consolidated statements of cash flows:

	As of June 30, 2022		As of December 31, 2021
Cash and cash equivalents	$	235,807	$	171,945
Restricted cash (included in other current assets)	—		1,648
Restricted cash (included in other assets)	750		750
Cash, cash equivalents and restricted cash in the statements of cash flows	$	236,557	$	174,343

Schedule of inventories

Inventory consisted of the following:

	As of June 30, 2022		As of December 31, 2021
Work-in-process	$	168,091	$	159,075
Finished goods	12,576		9,269
Total inventories	180,667		168,344
Less noncurrent inventories(1)	74,106		87,736
Total inventories classified as current	$	106,561	$	80,608

(1) Included in other assets on the condensed consolidated balance sheets. There are no recoverability issues for these amounts.

Schedule of prepaid expenses

Prepaid expenses consisted of the following:

	As of June 30, 2022		As of December 31, 2021
Prepaid clinical trial costs	$	59,996	$	42,578
Prepaid manufacturing	1,152		17,448
Prepaid commercial costs	26,940		15,732
Other prepaid expenses	12,272		13,080
Prepaid expenses	$	100,360	$	88,838

Schedule of accrued expenses and other current liabilities

Accrued expenses and other current liabilities consisted of the following:

	As of June 30, 2022		As of December 31, 2021
Accrued development milestones	$	25,000	$	5,000
Accrued employee compensation and benefits	35,917		40,109
Accrued clinical trial costs	34,822		37,477
Accrued commercialization and other professional fees	31,793		19,994
Accrued sales discounts and allowances	292,292		203,760
Current obligation to perform R&D services	30,303		22,030
Other accrued expenses and other current liabilities	95,180		91,649
Accrued expenses and other current liabilities	$	545,307	$	420,019